Purchase this article with an account.
lucia comastri, Matias Iglicki, Juan Pablo Francos, Juan Manuel Cortalezzi, Diego Bar, Carmen N Demetrio, Mario J Saravia, Jorge Bar, Pablo Chiaradia, Marcelo Zas, Retina Section, Ophthalmology Department, Hospital de Clinicas, University of Buenos Aires; Effects of the treatment with intravitreal injection of Ranibizumab for Diabetic Macular Edema.Our Experience: 30 month Follow up. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1769. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To present the effects of the treatment with intravitreal injection of Ranibizumab (lucentis) for Diabetic Macular Edema:
The Study included 8 patients with diabetic macular edema with or whiout previous Argon LASER and with or whitout previous neovascularization.The diagnosis and monitoring of the treatment were done by means of best correction visual acuity ( BCVA) with ETDRS chart , symptoms, fluorescein angigraphy and optical coherence tomography ( OCT) . The patients were monitored 7 and 30 days after the injection
30 days after the injection of ranibizumab (Lucentis) 0,05mg (0,5ml), BCVA had improved in 7 of 8 patients; they had improved 3 lines at reading letters on the ETDRS chart. The OCT showed an improvement in the retinal architecture in all patients: the retinal thickness reduced an average of 60 micrometres and has remained at that level up to the present (30 months follow-up).
One of the causes of diabetic macular edema is the increase of the permeability of the hematoretinal barrier, the VEGF is an important factor in this kind of increase. Thus, anti VEGF could be a possible treatment for this pathology. Further follow-up of the BCVA, OCT and symptoms is needed to decide whether retreatment is required.
This PDF is available to Subscribers Only